While a cure might be far off, concerted efforts targeting disease modification are ramping up
We need to find a cure for a disease for which we do not know the cause, have no diagnostic test, and strongly suspect is multifactorial, leading to significant heterogeneity. Two hundred years after its initial description, this is precisely where we find ourselves with Parkinson disease. By the time a patient is first diagnosed, there has been significant cell death and, as such, it seems likely that at best any disease-modifying therapy will arrest or, more likely, only slow continued cell death. While data from the recent phase 2 study repurposing the diabetes treatment exenatide offer hope,1 the field has previously been disappointed by a catalogue of trials that have failed to translate into clinical practice. While clearly too brief, it is hoped that this article will provide the reader with some appreciation of this rapidly expanding topic.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.